Your browser doesn't support javascript.
loading
Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.
Eckstein, Olive S; Visser, Johannes; Rodriguez-Galindo, Carlos; Allen, Carl E.
Affiliation
  • Eckstein OS; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, TX.
  • Visser J; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Rodriguez-Galindo C; Department of Paediatric Haematology and Oncology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom; and.
  • Allen CE; Department of Oncology and.
Blood ; 133(15): 1691-1694, 2019 04 11.
Article in En | MEDLINE | ID: mdl-30718231
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Histiocytosis, Langerhans-Cell / Proto-Oncogene Proteins B-raf Limits: Child / Humans Language: En Journal: Blood Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Histiocytosis, Langerhans-Cell / Proto-Oncogene Proteins B-raf Limits: Child / Humans Language: En Journal: Blood Year: 2019 Type: Article